Foghorn Therapeutics is a leader in chromatin biology, focusing on drugging challenging targets implicated in up to 50% of all tumors.
The company's innovative approaches aim to unlock selectivity in previously undruggable targets, positioning them as first-and-best-in-class.
Through strategic partnerships and multiple programs, Foghorn is at the forefront of developing therapies that leverage the chromatin regulatory system.
Chromatin Regulation Focus
Targeting chromatin regulation in tumors with multi-billion dollar opportunities.
Selectivity Achievement
Successful development of selective inhibitors for solid tumors and NSCLC.
Strategic Partnerships
Collaborations driving multiple innovative programs in chromatin biology.
- Foghorn Therapeutics has identified potential in up to 10% of NSCLC and 5% of all solid tumors, addressing challenges faced by the industry in developing selective inhibitors.
- Their focus on synthetic lethality and lineage dependencies presents a promising approach in cancer therapeutics.
- The company's achievements in selective target engagement and protein degradation technologies set them apart in the field of chromatin biology.
Foghorn Therapeutics' achievements in achieving selectivity in chromatin targets underscore their pivotal role in advancing precision therapeutics for challenging tumors. With a strong focus on innovation and strategic partnerships, Foghorn is poised for further breakthroughs in the field of chromatin biology.